Calendario›BIIB›BIIB014 · MOBILE

BIIB014 · MOBILE

Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease

Ensayo de BIOGEN INC. en Enfermedad de Parkinson.

Más ensayos de: Enfermedad de Parkinson.

Fase

Fase 2

Estado

Completado

Participantes

36

previstos

Centros

10

Fin del objetivo primario

dic 2008

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en ago 2007.

Qué mide

Numero y proporcion de sujetos con acontecimientos adversos (up to end of study) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is tolerated when given at different doses to patients with early-stage Parkinson's Disease. This study will also explore: * How BIIB014 is affected when given to patients with early-stage Parkinson's Disease (this will be done by measuring the levels of BIIB014 in the blood at several different times during the study), and * The activity of BIIB014 when given to early Parkinson's patients (this will be done by performing different Parkinson's Disease assessments and other tests during the study). Patients who enter this study will be randomly assigned to receive either BIIB014 or a placebo but because the study is blinded, neither they nor their study doctor will know which study treatment they are taking.

Más ensayos de BIIB

Todos los de BIIB, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT00442780), actualizada en ene 2009.